Literature DB >> 30820436

Dysbiosis of the Gut Microbiota on the Inflammatory Background due to Lack of Suppressor of Cytokine Signalling-1 in Mice.

Yoshiko Gendo1,2, Takashi Matsumoto3, Naganori Kamiyama1, Benjawan Saechue1, Ciaki Fukuda1, Astri Dewayani1, Shinya Hidano1, Kaori Noguchi1, Akira Sonoda1,2, Takashi Ozaki1, Nozomi Sachi1, Haruna Hirose1, Sotaro Ozaka1, Yuki Eshita1, Kazuhiro Mizukami2, Tadayoshi Okimoto2, Masaaki Kodama2, Tomoko Yoshimatsu4, Haruto Nishida4, Tsutomu Daa4, Yoshio Yamaoka3, Kazunari Murakami2, Takashi Kobayashi1.   

Abstract

BACKGROUND: Both environmental and genetic factors have been implicated in the induction of autoimmune disease. Therefore, it is important to understand the pathophysiological significance of the gut microbiota and host genetic background that contribute to an autoimmune disease such as inflammatory bowel disease (IBD). We have previously reported that mice deficient for suppressor of cytokine signaling-1 (SOCS1), in which SOCS1 expression was restored in T and B cells on an SOCS1-/- background (SOCS1-/-Tg mice), developed systemic autoimmune diseases accompanied by spontaneous colitis.
METHODS: To investigate whether the proinflammatory genetic background affects the gut microbiota, we used SOCS1-/-Tg mice as a model of spontaneous chronic colitis. Fecal samples were collected from SOCS1-/-Tg mice and SOCS1+/+Tg (control) mice at 1 and 6 months of age, and the fecal bacterial 16S ribosomal RNA genes were sequenced using the Illumina MiSeq platform.
RESULTS: Gut microbial diversity was significantly reduced and the intestinal bacterial community composition changed in SOCS1-/-Tg mice in comparison with the control mice. Interestingly, the population of Prevotella species, which is known to be elevated in ulcerative colitis and colorectal cancer patients, was significantly increased in SOCS1-/-Tg mice regardless of age.
CONCLUSION: Taken together, these results suggest that the proinflammatory genetic background owing to SOCS1 deficiency causes dysbiosis of the gut microbiota, which in turn generates a procolitogenic environment.

Entities:  

Keywords:  Colitis; Dysbiosis; Genetic factors; Prevotella; Suppressor of cytokine signaling-1

Year:  2019        PMID: 30820436      PMCID: PMC6390416          DOI: 10.1159/000495462

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  44 in total

1.  Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease.

Authors:  Paola Lovato; Christine Brender; Jørgen Agnholt; Jens Kelsen; Keld Kaltoft; Arne Svejgaard; Karsten Wessel Eriksen; Anders Woetmann; Niels Ødum
Journal:  J Biol Chem       Date:  2003-03-03       Impact factor: 5.157

2.  Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases.

Authors:  Jonas Mudter; Benno Weigmann; Brigitte Bartsch; Ralf Kiesslich; Dennis Strand; Peter R Galle; Hans A Lehr; Jan Schmidt; Markus F Neurath
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

3.  SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality.

Authors:  J C Marine; D J Topham; C McKay; D Wang; E Parganas; D Stravopodis; A Yoshimura; J N Ihle
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

4.  Prevotella enzymes involved in mucin oligosaccharide degradation and evidence for a small operon of genes expressed during growth on mucin.

Authors:  D P Wright; D I Rosendale; A M Robertson
Journal:  FEMS Microbiol Lett       Date:  2000-09-01       Impact factor: 2.742

5.  Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity.

Authors:  Toshikatsu Hanada; Hiroki Yoshida; Seiya Kato; Kentaro Tanaka; Kohsuke Masutani; Jun Tsukada; Yoshio Nomura; Hiromitsu Mimata; Masato Kubo; Akihiko Yoshimura
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

6.  Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta.

Authors:  Masahiro Yamamoto; Soh Yamazaki; Satoshi Uematsu; Shintaro Sato; Hiroaki Hemmi; Katsuaki Hoshino; Tsuneyasu Kaisho; Hirotaka Kuwata; Osamu Takeuchi; Koichiro Takeshige; Tatsuya Saitoh; Shoji Yamaoka; Naoki Yamamoto; Shunsuke Yamamoto; Tatsushi Muta; Kiyoshi Takeda; Shizuo Akira
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

7.  IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.

Authors:  Florian R Greten; Lars Eckmann; Tim F Greten; Jin Mo Park; Zhi-Wei Li; Laurence J Egan; Martin F Kagnoff; Michael Karin
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

8.  Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.

Authors:  Masahiro Yamamoto; Shintaro Sato; Hiroaki Hemmi; Katsuaki Hoshino; Tsuneyasu Kaisho; Hideki Sanjo; Osamu Takeuchi; Masanaka Sugiyama; Masaru Okabe; Kiyoshi Takeda; Shizuo Akira
Journal:  Science       Date:  2003-07-10       Impact factor: 47.728

9.  CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation.

Authors:  A Suzuki; T Hanada; K Mitsuyama; T Yoshida; S Kamizono; T Hoshino; M Kubo; A Yamashita; M Okabe; K Takeda; S Akira; S Matsumoto; A Toyonaga; M Sata; A Yoshimura
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

10.  MUSCLE: a multiple sequence alignment method with reduced time and space complexity.

Authors:  Robert C Edgar
Journal:  BMC Bioinformatics       Date:  2004-08-19       Impact factor: 3.169

View more
  2 in total

1.  Modulation of JNK-1/ β-catenin signaling by Lactobacillus casei, inulin and their combination in 1,2-dimethylhydrazine-induced colon cancer in mice.

Authors:  Mohammed S Ali; Rasha M Hussein; Yasser Gaber; Olfat A Hammam; Mohamed A Kandeil
Journal:  RSC Adv       Date:  2019-09-17       Impact factor: 4.036

Review 2.  RNA Modification in Inflammatory Bowel Diseases.

Authors:  Mika Nakayama; Yuki Ozato; Yoshiko Tsuji; Yasuko Arao; Chihiro Otsuka; Yumiko Hamano; Genzo Sumi; Ken Ofusa; Shizuka Uchida; Andrea Vecchione; Hideshi Ishii
Journal:  Biomedicines       Date:  2022-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.